Zihan Xue

Zihan Xue

Auto-generated profile, based on publicly available information

Zihan Xue

Department of Urology The Second Hospital of Tianjin Medical University Tianjin China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2025 in Cancer Science
Verified
Journal Article
Open access
ZXZihan Xue
Zihan Xue
YQYunkai Qie
Yunkai Qie
CSChong Shen
Chong Shen
ZWZhouliang Wu
Zhouliang Wu
HCHouyuan Chen
Houyuan Chen
HHHailong Hu
Hailong Hu
Repeat transurethral resection of bladder tumor (re‐TURBT) is commonly recommended for patients with non–muscle‐invasive bladder cancer (NMIBC) with high‐risk features, although many individuals may undergo unnecessary procedures that increase morbidity without clear benefit. Urinary tumor DNA (utDNA) has emerged as a promising biomarker, and we evaluated the performance of a multidimensional utDNA assay (utLIFE) in this context. In a retrospective cohort of 161 patients who underwent re‐TURBT between May 2020 and May 2025, urine samples collected 2–6 weeks after initial TURBT were analyzed using utLIFE, which integrates shallow whole‐genome sequencing and targeted sequencing of 155 genes with machine learning–based classification. Residual tumor was identified in 35% of patients, and utLIFE demonstrated high diagnostic accuracy, with sensitivity of 80.7%, specificity of 96.2%, and overall accuracy of 90.7%, markedly outperforming urine cytology. A positive utLIFE result was the strongest independent predictor of residual disease (OR = 77.5, 95% CI: 22.4–268.2, p < 0.001). During a median follow‐up of 32.5 months, recurrence occurred in 20.5% of patients; recurrence was defined as urothelial tumor relapse within the urinary tract and did not include distant metastasis. utLIFE positivity was significantly associated with shorter recurrence‐free survival (HR = 16.4, 95% CI: 2.7–101.8, p = 0.003). Longitudinal testing further revealed that utDNA positivity frequently preceded cystoscopic evidence of recurrence by several months. These findings highlight the strong diagnostic and prognostic value of utDNA in identifying residual disease and predicting recurrence, supporting its potential role in refining postoperative management strategies for NMIBC.

26 March 2026 in JCO Oncology Practice
Verified
Journal Article
Open access
ZXZihan Xue
Zihan Xue
YQYunkai Qie
Yunkai Qie
SLShan Liang
Shan Liang
RLRongjiang Li
Rongjiang Li
CSChong Shen
Chong Shen
HHHailong Hu
Hailong Hu
PURPOSE: The optimal adjuvant treatment approach for muscle-invasive bladder cancer (MIBC) remains unsettled. The IMvigor011 trial demonstrated that circulating tumor DNA (ctDNA)–guided adjuvant atezolizumab improves outcomes and advances precision oncology in this setting. However, the socioeconomic value of this biomarker-driven strategy is unclear. We therefore assessed the economic value of ctDNA-guided therapy in this postoperative setting. MATERIALS AND METHODS: We constructed a three-state Markov model to estimate costs, quality-adjusted life-years (QALYs), incremental net monetary benefit (INMB), and incremental cost-effectiveness ratios (ICERs) in patients with MIBC. The model compared a ctDNA-guided adjuvant atezolizumab strategy with the standard of care (SOC) from a US health care payer perspective. Cost-effectiveness was assessed across willingness-to-pay (WTP) thresholds of $50,000-$150,000 in US dollars (USD) per QALY, and model robustness was examined through comprehensive sensitivity analyses. RESULTS: Over a 5-year horizon, the ctDNA-guided strategy yielded 3.05 QALYs at a cost of $78,796 USD, compared with 2.92 QALYs and $131,601 USD for SOC. This corresponded to an ICER of –$397,163 USD per QALY gained, demonstrating dominance through greater benefit at lower cost. Sensitivity analyses confirmed that the ctDNA-guided approach was consistently cost-effective across all WTP thresholds. CONCLUSION: ctDNA-guided atezolizumab adjuvant therapy proves to be a cost-effective strategy for MIBC, optimizing health care resource allocation and reducing overtreatment while improving patient outcomes. More standardized ctDNA testing protocols and transparent reporting of ctDNA status distributions are essential.

27 September 2026 in Advanced Science
Verified
Journal Article
Open access
PDF file
LWLinhui Wang
Linhui Wang
XLXiaomeng Liu
Xiaomeng Liu
TZTao Zhu
Tao Zhu
ZSZirun Su
Zirun Su
RLRuiping Liu
Ruiping Liu
HHHailong Hu
Hailong Hu
Cisplatin (CDDP) chemosensitivity and severe toxicity severely limit its clinical application in muscle‐invasive bladder cancer (MIBC) and non‐muscle‐invasive bladder cancer (NMIBC). To address these unmet clinical needs, we synthesized a series of melatonin‐conjugated platinum(IV) prodrugs functionalized with isocyanate chains (compounds 5 ‒ 12 ), and identified MP‐12C (compound 11 ) as the lead candidate with optimal potency and safety. In vitro assays showed that MP‐12C exhibited far stronger antiproliferative activity than CDDP and mitomycin C in parental and CDDP‐resistant bladder cancer cells. Multiple in vivo models, including subcutaneous xenograft, orthotopic, and chemically induced spontaneous bladder cancer models, were adopted. Both intravenous injection and intravesical instillation of MP‐12C achieved robust tumor suppression while reducing toxicity compared to conventional chemotherapeutics. Mechanistically, MP‐12C downregulated the TCF4/COL6A3 axis to suppress collagen VI secretion by bladder cancer cells, thereby remodeling the extracellular matrix (ECM) and enhancing the sensitivity of bladder cancer cells to CDDP. MP‐12C triggered immunogenic cell death and persistently activated the cGAS‐STING pathway, promoting dendritic cell maturation and CD8 + T cell infiltration to remodel the antitumor immune microenvironment. Collectively, MP‐12C integrates ECM modulation and immune activation to exert superior anti‐bladder cancer efficacy with favorable safety, thus providing a promising platinum(IV) prodrug strategy for NMIBC and MIBC.

1 November 2026 in JCO Precision Oncology
Verified
Journal Article
Closed access
SHShiwang Huang
Shiwang Huang
ZXZihan Xue
Zihan Xue
NKNing Kang
Ning Kang
BMBoyue Ma
Boyue Ma
KJKaipeng Jia
Kaipeng Jia
YQYunkai Qie
Yunkai Qie
Purpose: Repeat transurethral resection of bladder tumor (TURBT) is recommended for selected patients with non–muscle-invasive bladder cancer (NMIBC), but clinicopathologic indications are broad and often identify no residual tumor. We tested whether postresection urinary tumor DNA (utDNA) adds value beyond guideline-derived repeat-TURBT selection and established recurrence risk models. Materials and Methods: This guideline-anchored cohort analysis included 161 patients with NMIBC who underwent repeat TURBT. Urine was collected 2 to 6 weeks after initial TURBT and before repeat TURBT. Tissue-naïve utDNA and cytology were compared with repeat-TURBT pathology and evaluated against repeat-TURBT indication sets, European Association of Urology (EAU) risk grouping, The European Organisation for Research and Treatment of Cancer (EORTC) models, and Club Urologico Espanol de Tratamiento Oncologico (CUETO) models. Results: Residual tumor was found in 57 patients (35.4%). Core, expanded, and carcinoma in situ-augmented core indication sets selected 73.3%, 88.2%, and 80.7% of patients. Within these indication-positive groups, utDNA-negative status identified 66.9% to 67.7% as lower-yield, although 9.1% to 10.4% still had residual tumor. Adding utDNA increased residual tumor AUCs from 0.544 to 0.891, 0.537 to 0.892, and 0.513 to 0.890 for the three indication sets, respectively. For any recurrence, c-indices increased from 0.602 to 0.774 for EAU risk grouping, 0.717 to 0.837 for EORTC models, and 0.770 to 0.824 for CUETO models after adding utDNA. Conclusion: Postresection utDNA refined residual tumor detection beyond repeat-TURBT indication sets and improved recurrence risk stratification beyond EAU/EORTC models, with directionally consistent CUETO results. Positive utDNA after negative repeat TURBT suggested occult molecular risk and supports prospective testing of utDNA-informed resection and surveillance algorithms.